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Summary
Background The estimated number of maternal deaths in 2013 worldwide was 289 000, a 45% reduction from 1990. 
Non-obstetric causes such as infectious diseases including tuberculosis now account for 28% of maternal deaths. In 
2013, 3·3 million cases of tuberculosis were estimated to occur in women globally. During pregnancy, tuberculosis is 
associated with poor outcomes, including increased mortality in both the neonate and the pregnant woman. The aim 
of our study was to estimate the burden of tuberculosis disease among pregnant women, and to describe how 
maternal care services could be used as a platform to improve case detection.
Methods We used publicly accessible country-level estimates of the total population, distribution of the total population 
by age and sex, crude birth rate, estimated prevalence of active tuberculosis, and case notiﬁ cation data by age and sex 
to estimate the number of pregnant women with active tuberculosis for 217 countries. We then used indicators of 
health system access and tuberculosis diagnostic test performance obtained from published literature to determine how 
many of these cases could ultimately be detected.
Findings We estimated that 216 500 (95% uncertainty range 192 100–247 000) active tuberculosis cases existed in 
pregnant women globally in 2011. The greatest burdens were in the WHO African region with 89 400 cases and the 
WHO South East Asian region with 67 500 cases in pregnant women. Chest radiography or Xpert RIF/MTB, delivered 
through maternal care services, were estimated to detect as many as 114 100 and 120 300 tuberculosis cases, respectively.
Interpretation The burden of tuberculosis disease in pregnant women is substantial. Maternal care services could 
provide an important platform for tuberculosis detection, treatment initiation, and subsequent follow-up.
Funding United States Agency for International Development.
Copyright © Sugarman et al. Open Access article distributed under the terms of CC BY-NC-SA.
Introduction
In the past two decades, there have been major declines 
in maternal mortality. The estimated number of maternal 
deaths in 2013 worldwide was 289 000, a 45% reduction 
from 1990.1 Globally, the leading causes of maternal 
death include direct obstetric causes, such as 
haemorrhage and hypertensive disorders; however, other 
non-obstetric causes including infectious diseases are 
now responsible for 28% of maternal mortality 
worldwide.2 Despite widespread implementation of the 
DOTS strategy and progress towards the tuberculosis-
speciﬁ c targets articulated in the Millennium 
Development Goals, tuberculosis remains a signiﬁ cant 
global public health challenge. In 2013, 3·3  million 
tuberculosis cases and 510 000 tuberculosis deaths were 
estimated to occur in women globally.3
The presence of tuberculosis disease during pregnancy, 
delivery, and post partum is known to result in unfavorable 
outcomes for both pregnant women and infants.4,5 These 
outcomes include a roughly two-fold increased risk of 
premature birth, low birthweight, intrauterine growth 
retardation, and a six-fold increase in perinatal death,6,7 
especially in women who are co-infected with HIV.4,8–11 
Tuberculosis disease in the infant is also an outcome of 
concern. In the high tuberculosis and HIV prevalence 
setting of Durban, South Africa, 15% of mothers with 
active tuberculosis transmitted the infection to their 
newborns within the ﬁ rst 3 weeks of life.6
Clinical diagnosis of tuberculosis in pregnant women 
can be diﬃ  cult due to non-speciﬁ c symptoms related to the 
physiological response to pregnancy.4 For pregnant women 
in most countries with a high tuberculosis burden, the 
current standard practice of care for tuberculosis screening 
and diagnosis is the same as that used to detect disease in 
the general population. Recommended diagnostic tests 
may include smear microscopy, culture, and molecular 
DNA detection methods such as Xpert MTB/RIF.4 Shielded 
chest radiography, which poses minimal risk to the fetus, is 
also recommended in women with a recent tuberculosis 
contact.4–6 In settings of high HIV burden, the WHO 
symptom screen and Xpert MTB/RIF are recommended. 
Once diagnosis is conﬁ rmed, the WHO recommendation 
for tuberculosis treatment in pregnant women is the same 
as for non-pregnant women,12 even for HIV-positive 
women on antiretroviral therapy (ART).5,12
The burden of tuberculosis disease among pregnant 
women is not known. Consequently, there are few data to 
guide eﬀ orts to reduce the tuberculosis burden in this 
population. Therefore, the objectives of this paper were to 
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(1) estimate the global and country-level burden 
of tuberculosis disease among pregnant women; 
(2) determine how many pregnant women could beneﬁ t 
from tuberculosis diagnosis integrated with maternity 
care; and (3) estimate the number of cases that could be 
detected using three diﬀ erent diagnostic tests.
Methods
Estimating the burden of tuberculosis in pregnant women
We derived an estimate of the number of pregnant women 
with active tuberculosis in 217 countries using publicly 
accessible country-level estimates of the following 
parameters: total population,13 distribution of the total 
population by age and sex,13 crude birth rate,14 estimated 
prevalence of active tuberculosis,15 and case notiﬁ cation 
data by age and sex.15 In each country, the estimated 
tuberculosis prevalence rate was adjusted to reﬂ ect more 
accurately the prevalence of tuberculosis among women 
of childbearing age (15–44 years) by using the ratio of 
smear-positive cases notiﬁ ed in women of childbearing 
age relative to the smear positive notiﬁ cation rate in the 
full population. The calculated adjusted tuberculosis 
prevalence rates by region are shown in table 1 together 
with case notiﬁ cation rates in women aged 15–44 years, 
and in the full population (as reported by WHO).16 The 
point estimate of tuberculosis cases in pregnant woman 




We multiplied the total population by the crude birth 
rate, and then by the average gestational period 
(280 days), to calculate the number of pregnant days, per 
country, in 2011. By dividing this number by 365 days, we 
estimated the number of women pregnant on any given 
day during the year. Finally, by multiplying this number 
by the age-speciﬁ c and sex-speciﬁ c tuberculosis 
prevalence, we calculated a point estimate of the number 
of pregnant women with active tuberculosis in each 
country in 2011. In summary, formula 1·1 was used to 
calculate the case notiﬁ cation rate in women aged 
15–44 years. This rate was used to estimate the total 
prevalence in women aged 15–44 years (formula 1·2). 
Formula 1·3 was then used to estimate the total number 
of tuberculosis cases in pregnant women. Country-level 
estimates were added together to generate regional and 
global estimates of tuberculosis burden.
Monte Carlo simulations were used to deﬁ ne the 
uncertainty ranges (UR; 2·5 and 97·5 percentiles) around 
point estimates. To calculate ranges, we used formulas 1·1 
to 1·3, and randomly and individually sampled three key 
parameters (crude birth rate, total population, and 
estimated prevalence of tuberculosis) 1000 times. Reported 
maxima and minima for each key input informed the 
variability of the distributions, which were assumed to be 
Gaussian based on best ﬁ t in comparison to other two-
tailed distributions. For each distribution, the mean was 
selected as the medium-level estimate of the primary 
data.12,13 The variance was deﬁ ned as three standard 
deviations from the mean, as the primary data sources 
provided high-level and low-level data that represented the 
highest and lowest possible data points.12,13
Estimating the burden of tuberculosis in pregnant 
women among those who access maternal health services
We estimated the proportion of tuberculosis cases with 
access to antenatal and labour or delivery care in each 
country by multiplying the country-level estimate of 
tuberculosis cases by two diﬀ erent indicators of access: at 
least one antenatal care visit (antenatal care services),17,18 
and birth attended by skilled health professional (labour 
and delivery services).18 The WHO regional averages for 
these statistics are shown in table 1.
Estimating the burden of tuberculosis detected in 
pregnant women
We present three hypothetical diagnostic scenarios, each 
using a diﬀ erent single test that could be implemented in 
the maternal care setting. Tests considered include: (1) 
the present standard of care for tuberculosis diagnosis in 
most settings (sputum smear microscopy); (2) a test that 
is currently recommended in pregnant women with high 
sensitivity but only moderate speciﬁ city (chest 
radiography for detection of active tuberculosis); and (3) 
a recently recommended test with high sensitivity and 
excellent speciﬁ city (Xpert RIF/MTB). WHO symptom 
screen with subsequent Xpert RIF/MTB was not explicitly 
Case notiﬁcation rate women (age 15–44 years) 
smear positive=
Total N new smear positive cases 
notiﬁed woman (15–44 years)
Full country population ×
proportion of population women age 15–44 years
Estimated tuberculosis prevalence rate women 
(age 15–44 years)
Case notiﬁcation rate woman
(age 15–44 years) smear positive
Full country case notiﬁcation rate smear positive
× Full country tuberculosis prevalence rate
Estimated tuberculosis prevalence rate women
(age 15–44 years)
Estimated number of tuberculosis cases 
in pregnant women=
Total population × crude birth rate ×
280 days per pregnancy
365 days per year
×
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considered because our Xpert RIF/MTB test scenario 
assumes that the full population would get Xpert RIF/
MTB as the initial test. These tests serve as examples, 
that could be more or less relevant, depending on the 
local epidemiology of the setting.
To assess the potential range of eﬀ ect of diﬀ erent tests, 
we assumed that, in each country, all pregnant women 
with access to antenatal and labour or delivery care would 
receive only the single tuberculosis test described in each 
diagnostic scenario. We assumed that women were only 
being diagnosed within the framework of maternal care 
services, and that the test oﬀ ered in these settings may 
diﬀ er from testing algorithms routinely oﬀ ered through 
the national tuberculosis programme.
We estimated the proportion of cases that could be 
detected using these tests for initial case detection by 
multiplying each country-level estimate (after adjustment 
for access to maternal health services) by the reported 
test sensitivity. Before investigating case detection by 
test, the adjusted country-level tuberculosis prevalence 
estimate was subdivided into diﬀ erent types of disease 
(pulmonary-smear positive, pulmonary-smear negative, 
or extra-pulmonary) with WHO data for disease 
classiﬁ cation by country.15 Estimates of test performance 
were obtained from the literature19,20 and are summarised 
in appendix. Test sensitivity in pregnant women was 
assumed to be the same as in the general population 
because there are no data to support other assumptions. 
At all stages of the analysis, any missing data were 
imputed with the average regional values from which the 
country in question was located. A summary of missing 
data by variable is shown in the appendix. All analysis 
was done in Microsoft Excel.
Role of the funding source
The funding agency had no role in study design, data 
collection and analysis, the decision to publish, or 
preparation of the manuscript. All authors had access to 
all of the data and were responsible for the decision to 
submit the report.
Results
We estimated that there were 216 500 (95% UR 
192 100–247 000) pregnant women with tuberculosis 
globally in 2011. The number of tuberculosis cases 
estimated in each of the 217 countries is provided in 
appendix. As shown in table 2, the Africa WHO Region 
and South East Asia WHO Region carry the greatest 
burden of tuberculosis cases among pregnant women, 
with 89 400 (41% of global burden) and 67 500 (31% of 
global burden) cases, respectively. The country with the 
highest number of cases in pregnant women was India 
(44 500 or 21% of the global tuberculosis burden), which 
reﬂ ects the high tuberculosis burden in the general 
population, the country’s large population, and its high 
birth rate. Estimates for each of the 22 WHO high 
tuberculosis burden countries are shown in table 3.
When we considered the proportion of tuberculosis 
cases with access to maternity services in each country 
that could potentially beneﬁ t from tuberculosis 
screening and diagnosis through either antenatal care 
or labour and delivery services, the number of 
tuberculosis cases that could be reached globally was 
167 200 (antenatal care) or 123 500 (labour and delivery; 
table 4). Results for each of the 217 countries are shown 
in the appendix.
Epidemiological data (rate per 100 000) Health system access (%)

















 Antenatal care 
services17,18 (at least 
one antenatal care 
visit)
Labour and delivery 
services18 (births 
attended by skilled 
health personnel)
African Region 70 96 293 411 84 60
Region of the Americas 13 11 36 34 95 90
Eastern Mediterranean Region 28 35 171 219 78 75
European Region 9 8 56 52 97 99
South-East Asia Region 59 54 271 250 83 68
Western Paciﬁ c Region 32 22 131 92 90 85
*Calculated using methods described in main text.
Table 1: Epidemiological prevalence data and health system access by WHO region
See Online for appendix
Mean (95% uncertainty 
range)






All countries combined 216 500 (192 100–247 000) 2·1 (1·8 – 2·4) ··
African Region 89 400 (74 200–110 500) 3·6 (3·0 – 4·5) 41%
Region of the Americas 4800 (3900–6000) 0·4 (0·3 – 0·5) 2%
Eastern Mediterranean Region 28 500 (19 700–41 900) 2·3 (1·6 – 3·4) 13%
European Region 4900 (3800–6300) 0·6 (0·5 – 0·8) 2%
South-East Asia Region 67 500 (52 000–87 100) 2·4 (1·9 – 3·1) 31%
Western Paciﬁ c Region 21 400 (19 400–23 700) 1·1 (1·0 – 1·2) 10%
Table 2: Total number of active tuberculosis cases in pregnant women, rate per 1000 pregnant women 
and percentage of global burden by WHO region and combined
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When test sensitivity was taken into account, the total 
number of cases that could potentially be detected further 
declined (table 5). Sputum smear microscopy yielded the 
fewest cases, because no smear-negative cases would be 
detected using this approach to diagnosis. A nucleic acid 
ampliﬁ cation test such as Xpert MTB/RIF would detect 
120 300 active tuberculosis cases in antenatal care settings 
and 89 000 in labour and delivery settings. Chest 
radiography was estimated to detect a similar number of 
cases: 114 100 and 84 500 respectively.
Discussion
Because access to maternity services has improved in 
low-resource settings and indirect causes contribute to a 
larger proportion of maternal deaths, it is important to 
understand the burden of infectious diseases such as 
tuberculosis among pregnant women. This study 
estimates that, in 2011, more than 200 000 pregnant 
women had active tuberculosis globally. More than 70% 
of these tuberculosis cases occurred in Africa and South 
East Asia, where access to quality maternity services 
remains limited and case detection rates are lower in the 
general population.3 This is the ﬁ rst study that has 
attempted to quantify the burden of tuberculosis disease 
among pregnant women, a key population for which 
speciﬁ c interventions to reduce morbidity and mortality 
are urgently needed in low-resource settings.4 It is a 
comprehensive study using consistently reported data 
across 217 countries based on routinely collected 
information provided to international authorities.
The active case ﬁ nding scenarios we describe oﬀ er the 
advantage of detecting tuberculosis in those with 
minimal clinical disease who would otherwise not be 
detected. It also oﬀ ers the additional advantage as a 
platform for isoniazid preventative therapy. Treatment 
for latent tuberculosis infection is recommended for 
pregnant women who are at high risk of disease 
progression.4 Maternity services provide a unique 
opportunity for tuberculosis screening and subsequent 
follow up, in view of a pregnant woman’s ongoing 
contact with the health system during antenatal care, 
labour and delivery, and afterwards, through maternal 
Health system indictor
Antenatal care 
services (at least one 
antenatal care visit)
Labour and delivery 
services (births 
attended by skilled 
health personnel)
African Region 71 100 49 600
Region of the Americas 4400 3500
Eastern Mediterranean 
Region
17 000 11 100
European Region 4700 4800
South-East Asia Region 51 000 37 200
Western Paciﬁ c Region 19 100 17 200
All countries combined 167 200 123 500
Table 4: Number of active tuberculosis cases in pregnant women who 
access antenatal and labour and delivery services, by WHO region and 
combined
Maternity care access indicator
Antenatal care services 
(at least one antenatal 
care visit)
Labour and delivery 
services (births 
attended by skilled 
health personnel)
Smear microscopy
Smear positive 85 000 62 600
Smear negative 0 0
Total 85 000 62 600
Chest radiography
Smear positive 80 000 58 900
Smear negative 34 200 25 600
Total 114 100 84 500
Xpert MTB/RIF
Smear positive 83 300 61 400
Smear negative 37 000 27 600
Total 120 300 89 000
Table 5: Number of active tuberculosis cases detected with diﬀ erent 
diagnostic tests in pregnant women—all countries combined
Mean (95% uncertainty 
range)
Rate per 1000 
pregnant women (95% 
uncertainty range)
Percentage of global 
burden among pregnant 
women*
Afghanistan 6100 (3200–11 000) 7·2 (3·7–12· 8) 2· 8%
Bangladesh 8100 (4100–14 300) 3·5 (1·8–6·1) 3· 8%
Brazil 800 (400–1600) 0·4 (0·2–0·7) 0·4%
Cambodia 1700 (1400–2000) 5·9 (5·0–7·0) 0·8%
China 9500 (8100–11 100) 0·7 (0·6–0·8) 4·4%
DR Congo 16 200 (8700–26 900) 7·2 (3·9–12·1) 7·5%
Ethiopia 8000 (6500–9600) 3·7 (3·0–4·4) 3·7%
India 44 500 (30 600–62 000) 2·3 (1·6–3·1) 20·6%
Indonesia 9500 (4700–16 400) 2·7 (1·3–4 ·6) 4·4%
Kenya 4300 (2200–7100) 3·8 (2·0–6·4) 2·0%
Mozambique 4300 (2300–7400) 5·9 (3·2–10·4) 2·0%
Myanmar 2500 (2000–3200) 3·9 (3·1–5·0) 1·2%
Nigeria 10 900 (3000–27 700) 2·1 (0·6–5·4) 5·0%
Pakistan 14 800 (7200–26 300) 4·3 (2·1–7·7) 6·8%
Philippines 6600 (5700–7500) 3·7 (3·2–4·2) 3·0%
Russia 1200 (500–2400) 0·9 (0·4–1·8) 0·5%
South Africa 8400 (4400–14 300) 10·3 (5·4–17·6) 3·9%
Tanzania 3100 (1700–5200) 2·2 (1·2–3·7) 1·4%
Thailand 500 (200–900) 0·9 (0·4–1·6) 0·2%
Uganda 2600 (1400–4400) 2·3 (1·2–3·8) 1·2%
Vietnam 900 (700–1100) 0·8 (0·7–1·0) 0·4%
Zimbabwe 2400 (1400–4100) 7·9 (4·6–13·4) 1·1%
Total 166 200 (143 000–195 500) 2·5 (2·1–2·9) 77·0%
*Total percentage does not sum to 100% because list only shows % of global burden in pregnant women for each of 
the WHO 22 high tuberculosis burden countries.
 Table 3: Total number of active tuberculosis cases in pregnant women, rate per 1000 pregnant women 
and percentage of global burden amongst pregnant women for the 22 high tuberculosis burden 
countries as classiﬁ ed by the WHO
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and child health services. Provision of treatment to 
women with active tuberculosis who are already 
integrated into the health system should optimise 
outcomes, oﬀ ering improved protection to both the 
mother and potentially reducing tuberculosis 
transmission to the neonate as well. This approach has 
proved to be successful for other infectious diseases. For 
example, malaria programmes have successfully 
leveraged these platforms to promote intermittent 
preventive treatment of malaria during pregnancy and 
provide insecticide-treated nets,21,22 which have beneﬁ ts 
beyond pregnancy and the postpartum period.
This study had several limitations. First, our estimates 
of burden among those who access the health system 
assume that access only occurs within maternity care 
settings (antenatal and labour and delivery). We do not 
account for pregnant women who could have been 
diagnosed through the national tuberculosis programme 
or other programmes because we have no data to 
estimate the extent to which they could gain access 
through other programmes. In many settings, especially 
among persons living with HIV, the prevalence of 
undiagnosed tuberculosis in pregnant women has been 
noted to be high.4,23 Because of our assumption about 
health system access, the number of pregnant women 
that could beneﬁ t from the integration of tuberculosis 
screening and diagnosis in maternal health settings will 
vary by setting. In settings where there is little coverage 
of the national tuberculosis programme or lower case 
detection in the general population, the added value of 
integration will be increased in terms of yielding cases 
among pregnant women—eg, where coverage of 
tuberculosis diagnosis services is limited to district 
hospitals, but pregnant women access antenatal care at 
more peripheral health services.
Second, the role of the private sector in provision of all 
of the relevant services for this model—tuberculosis 
screening and diagnosis, routine antenatal care, labour 
and delivery care—is not known at the global level, but is 
likely to be signiﬁ cant in high tuberculosis burden 
settings in Asia. The integration of these services should 
be considered in view of these programmatic contexts. 
Third, most of the data we used to derive our estimates 
were obtained from publicly accessible databases that 
have uncertainty arising from diﬀ erent sources. For 
example, for epidemiological data, in settings such as 
India, where as many as half of patients with tuberculosis 
are treated in the private sector,24 under-reporting leads 
to underestimates of the true burden of tuberculosis 
disease. Related to this, we assumed that tuberculosis 
cases were not systematically undernotiﬁ ed in any 
particular sex or age group. We do not have data to 
support other assumptions, but if in fact tuberculosis 
cases are undernotiﬁ ed in women of reproductive age, 
the estimates presented will be an underestimate of the 
true burden of disease in pregnant women. Finally, 
when considering diﬀ erent diagnostic tests, we assumed 
that chest radiography, a recommended test for initial 
detection of tuberculosis disease in pregnant women,6 is 
accessible wherever skilled birth attendants are 
practising. Although it might not be used in all settings 
in current practice, evidence shows that use of this 
technology in countries with low or middle income, 
especially in high HIV burden settings, could be 
advantageous.25,26 Additionally, if active tuberculosis can 
be ruled out with radiography, other abnormalities 
consistent with previous tuberculosis infection (eg, 
apical ﬁ bronodular scarring) might be detected and 
isoniazid preventative therapy can be oﬀ ered.
With these considerations in mind, this study provides 
useful information for stakeholders at all levels as they 
work to optimise care for pregnant women and those 
with tuberculosis (panel). Getahun and colleagues4 have 
urged the integration of tuberculosis care programmes 
and maternal, neonatal, and child health services to 
ensure the mainstreaming of tuberculosis services. We 
have shown that more sensitive tests such as Xpert RIF/
MTB could be valuable tests in this population, and ﬁ eld 
trials from a study in Zambia have shown promising 
results.27 Computer models of integrated screening with 
Xpert RIF/MTB have also been described in this 
setting.28 However, further research is urgently needed 
in this vulnerable population,5 especially around 
appropriate service delivery models to evaluate, 
integrate, and optimise uptake of services among 
providers and beneﬁ ciaries. When, how often, and 
where to screen during pregnancy are all questions that 
need to be considered. For example, should tuberculosis 
Panel: Research in context
Systematic review
We searched PubMed with the terms “tuberculosis”, “pregnancy”, and “burden” with no 
language or date restrictions. We identiﬁ ed 60 articles; however, none provided a 
quantitative estimate of the global burden of tuberculosis disease in pregnant women. We 
then search PubMed with the terms “tuberculosis” and “maternal child health”. We identiﬁ ed 
several review studies that described the epidemiology of disease in pregnant women in 
countries with low and middle income and summarised the latest evidence on unfavourable 
outcomes associated with tuberculosis for both the pregnant women and infant. Published 
articles were also identiﬁ ed that provided information about present screening practices in 
pregnant women in high burden settings and about interventions designed to increase the 
detection of disease in this population. Further studies of relevance were identiﬁ ed through 
reports identiﬁ ed in the preliminary search.
Interpretation
This study adds to the present body of evidence by providing a quantitative estimate of 
the burden of tuberculosis disease in pregnant women. It also provides estimates of the 
potential eﬀ ect of several diagnostic tests used in 217 countries, with diﬀ erent levels of 
access through maternal care platforms. Our study suggests that in many countries with 
low and middle income, pregnant women carry a substantial burden of tuberculosis, and 
that maternal care platforms could be an eﬃ  cient way to detect additional cases that 
might otherwise remain undetected. The results can inform ongoing scale-up and 
integration of interventions that are intended to address a wide range of maternal health 
concerns related to infectious disease, including HIV and malaria.
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diagnosis be available in the antenatal care setting, or 
should pregnant women be screened in these settings 
but visit another location for further testing? The 
question of cost should also be considered because 
more screening will increase costs to health systems, 
many of which are already ﬁ nancially strained.
In high HIV prevalence settings any active case 
ﬁ nding for tuberculosis should have a substantial eﬀ ect. 
In 2012, WHO estimated that 37% of incident 
tuberculosis cases in the African Region were co-
infected with HIV. As many of these cases will be in 
women of reproductive age, focusing screening eﬀ orts 
on this population is essential. Routine HIV-related 
inter ventions such as Prevention of Mother to Child 
Transmission (PMTCT) could serve as a gateway to 
introduce tuberculosis screening, diagnosis, and 
treatment. How best to do this has already been 
considered in diﬀ erent areas of South Africa.8,23,29,30 In 
many high tuberculosis burden countries, Option B+ 
(life-long treatment of HIV-positive pregnant women 
regardless of CD4 levels) has been fully adopted by 
WHO.31 The programme is being rolled out in many 
countries, often integrated with routine antenatal and 
delivery care services. The rollout of these services could 
provide a unique opportunity for integrated service 
delivery to insure optimum care for all pregnant women.
Any improvement to tuberculosis services aimed at 
pregnant women will reduce transmission between 
mothers and infants, and should ultimately lead to a 
reduction in secondary cases in children, an important 
subpopulation in which the burden of disease is now 
thought to be much higher than originally estimated.32 
The substantial burden of disease estimated in pregnant 
women indicates there remains an urgent need to 
improve access to tuberculosis screening and diagnosis, 
especially in high tuberculosis and high HIV burden 
settings. More research is imperative to improve delivery 
and uptake of care in this vulnerable population.
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